Intellia Achieves Gene-Editing Breakthrough With First In Vivo CRISPR Therapy

Promise Of Safe And Effective Gene Editing Takes Step Forward

 
• By Andrew McConaghie

The first use of CRISPR/Cas9 in humans shows promising safety and efficacy against rare disease ATTR, and opens up the possibility of treating many genetic diseases.

Intellia Therpeutics
Intellia's in vivo CRISPR therapies could rival other modalities, such as viral vector-based gene therapies and RNAi therapies. • Source: Intelllia

More from Business

More from Scrip